Skip to content
Browse

Edition

Sections

Appearance

AboutSourcesContactPrivacy

Why Indian drugmakers are losing pricing power in the US

Powerful buyers, the end of limits on generic Revlimid and fast-fading launches are squeezing Indian drugmakers' US business. Complex products offer a way to protect pricing power, but developing them requires higher R&D spending and years of investment before they can replace lost revenue.

First reported by Mint 1 source
Image: Mint
Image: Mint
Read at Mint(opens in a new tab)

Full coverage

Every report we found on this story, oldest first. Each links to the original publisher.

  1. Mint

    Why Indian drugmakers are losing pricing power in the US (opens Mint in a new tab)

    Powerful buyers, the end of limits on generic Revlimid and fast-fading launches are squeezing Indian drugmakers' US business. Complex products offer a way to protect pricing power, but developing them requires higher R&D spending and years of investment…

Something wrong with how we've grouped or summarised this story? Report a problem